NAFLD significantly reduced the gene expression of NR1H4 compared to the control, YCHT treatment could raise the NR1H4 mRNA level, but only YCHT M was statistically different from the NAFLD group (Fig. 8G). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.